Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier

European Journal of Pharmacology

Volumn 659, Issue 2-3, 2011, Pages 124-129

  Bachmeier, Corbin ^a   Beaulieu Abdelahad, David ^a   Mullan, Michael ^a   Paris, Daniel ^a  

^a ROSKAMP INSTITUTE   (United States)

Author keywords

amyloid; Alzheimer's disease; Blood brain barrier; Dihydropyridine

Indexed keywords

AMLODIPINE; AMYLOID BETA PROTEIN[1-42]; AZELNIDIPINE; CILNIDIPINE; DIHYDROPYRIDINE DERIVATIVE; LERCANIDIPINE; NICARDIPINE; NILVADIPINE; NIMODIPINE; NITRENDIPINE; PLACEBO;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSCYTOSIS; WILD TYPE;

AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; DIHYDROPYRIDINES; FEMALE; HUMANS; MEMORY; MICE; PEPTIDE FRAGMENTS; SPATIAL BEHAVIOR; TRANSCYTOSIS;

EID: 79955941709     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.048     Document Type: Article

References (41)

1. Artursson, P., 1990. Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79, 476-482.
2. Bachmeier, C., Mullan, M., Paris, D., 2010. Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood-brain barrier. Cytotechnology 62, 519-529.
3. Boche, D., Nicoll, J.A., Weller, R.O., 2005. Immunotherapy for Alzheimer's disease and other dementias. Curr. Opin. Neurol. 18, 720-725.
4. Citron, M., 2010. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387-398.
5. de la Torre, J.C., Stefano, G.B., 2000. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res. Brain Res. Rev. 34, 119-136.
6. Deane, R., Du Yan, S., Submamaryan, R.K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A.M., Armstrong, D.L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D., Zlokovic, B., 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913.
7. Deane, R., Wu, Z., Zlokovic, B.V., 2004. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631. (Pubitemid 39458354)
8. DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M., Holtzman, D.M., 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98, 8850-8855.
9. Farina, P., Targa, G., Leoni, B., Tajana, A., 1997. Pharmacokinetics of lercanidipine in animals: II. Distribution to and elimination from organs and tissues after administration of [14C]lercanidipine to rats and dogs. Whole-body autoradiography, biliary excretion and enterohepatic circulation and biotransformation in rats. J. Cardiovasc. Pharmacol. 29, S97-S108.
10. Farkas, E., Luiten, P.G., 2001. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64, 575-611.
11. Forette, F., Seux, M.L., Staessen, J.A., Thijs, L., Birkenhager, W.H., Babarskiene, M.R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., Laks, T., Lilov, E., Moisseyev, V., Tuomilehto, J., Vanhanen, H., Webster, J., Yodfat, Y., Fagard, R., 1998. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 352, 1347-1351. (Pubitemid 28510916)
12. Forette, F., Seux, M.L., Staessen, J.A., Thijs, L., Babarskiene, M.R., Babeanu, S., Bossini, A., Fagard, R., Gil-Extremera, B., Laks, T., Kobalava, Z., Sarti, C., Tuomilehto, J., Vanhanen, H., Webster, J., Yodfat, Y., Birkenhager, W.H., 2002. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162, 2046-2052.
13. Fritze, J., Walden, J., 1995. Clinical findings with nimodipine in dementia: test of the calcium hypothesis. J. Neural. Transm. Suppl. 46, 439-453.
14. Hanyu, H., Hirao, K., Shimizu, S., Sato, T., Kiuchi, A., Iwamoto, T., 2007. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int. J. Geriatr. Psychiatry 22, 1264-1266.
15. Holscher, C., Gengler, S., Gault, V.A., Harriott, P., Mallot, H.A., 2007. Soluble beta-amyloid [25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur. J. Pharmacol. 561, 85-90.
16. Hu, N.W., Smith, I.M., Walsh, D.M., Rowan, M.J., 2008. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain 131, 2414-2424.
17. Kalaria, R.N., 1999. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann. N. Y. Acad. Sci. 893, 113-125.
18. Khachaturian, A.S., Zandi, P.P., Lyketsos, C.G., Hayden, K.M., Skoog, I., Norton, M.C., Tschanz, J.T., Mayer, L.S., Welsh-Bohmer, K.A., Breitner, J.C., 2006. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 63, 686-692.
19. LaFerla, F.M., Green, K.N., Oddo, S., 2007. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8, 499-509.
20. Lindgren, M., Thostrup, H., Svannäs, M., Fagher, B., 2000. Felodipine in patients with organic solvent-induced chronic toxic encephalopathy: a double-blind, crossover study. Clin. Drug. Inv. 19, 267-276.
21. Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E., Rogers, J., 1999. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862.
22. Matsuoka, Y., Saito, M., LaFrancois, J., Saito, M., Gaynor, K., Olm, V., Wang, L., Casey, E., Lu, Y., Shiratori, C., Lemere, C., Duff, K., 2003. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23, 29-33. (Pubitemid 36050401)
23. Maxwell, C.J., Hogan, D.B., Ebly, E.M., 1999. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ 161, 501-506. (Pubitemid 29433523)
24. McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I., Masters, C.L., 1999. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866.
25. Mizoguchi, H., Takuma, K., Fukuzaki, E., Ibi, D., Someya, E., Akazawa, K.H., Alkam, T., Tsunekawa, H., Mouri, A., Noda, Y., Nabeshima, T., Yamada, K., 2009. Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice. J. Pharmacol. Exp. Ther. 331, 14-22.
26. Mogi, M., Li, J.M., Tsukuda, K., Iwanami, J., Min, L.J., Sakata, A., Fujita, T., Iwai, M., Horiuchi, M., 2008. Telmisartan prevented cognitive decline partly due to PPARgamma activation. Biochem. Biophys. Res. Commun. 375, 446-449.
27. Morris, R.G.M., 1981. Spatial localisation does not require the presence of local cues. Learn. Motiv. 12, 239-260.
28. Murray, M.D., Lane, K.A., Gao, S., Evans, R.M., Unverzagt, F.W., Hall, K.S., Hendrie, H., 2002. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch. Intern. Med. 162, 2090-2096.
29. Paris, D., Humphrey, J., Quadros, A., Patel, N., Crescentini, R., Crawford, F., Mullan, M., 2003. Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol. Res. 25, 642-651.
30. Paris, D., Ait-Ghezala, G., Mathura, V.S., Patel, N., Quadros, A., Laporte, V., Mullan, M., 2005. Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells. Brain Res. Mol. Brain Res. 136, 212-230.
31. Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., Mullan, M.J., 2011. Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier. Mol. Med. 17, 149-162.
32. Sagare, A., Deane, R., Bell, R.D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P.J., Wu, Z., Zarcone, T., Goate, A., Mayo, K., Perlmutter, D., Coma, M., Zhong, Z., Zlokovic, B.V., 2007. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13, 1029-1031.
33. Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L.S., Doody, R., van Dyck, C.H., Mulnard, R., Barakos, J., Gregg, K.M., Liu, E., Lieberburg, I., Schenk, D., Black, R., Grundman, M., 2009. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
34. Selkoe, D.J., 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
35. Shibata, M., Yamada, S., Kumar, S.R., Calero, M., Bading, J., Frangione, B., Holtzman, D.M., Miller, C.A., Strickland, D.K., Ghiso, J., Zlokovic, B.V., 2000. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499.
36. Sisodia, S.S., Price, D.L., 1995. Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 9, 366-370.
37. Todd Roach, J., Volmar, C.H., Dwivedi, S., Town, T., Crescentini, R., Crawford, F., Tan, J., Mullan, M., 2004. Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. Brain Res. 1015, 161-168. (Pubitemid 38829750)
38. Tollefson, G.D., 1990. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol. Psychiatry 27, 1133-1142. (Pubitemid 20150025)
39. Tsukuda, K., Mogi, M., Iwanami, J., Min, L.J., Sakata, A., Jing, F., Iwai, M., Horiuchi, M., 2009. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferatoractivated receptor-gamma activation. Hypertension 54, 782-787.
40. Uchida, S., Yamada, S., Nagai, K., Deguchi, Y., Kimura, R., 1997. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 61, 2083-2090. (Pubitemid 27478835)
41. Yasar, S., Corrada, M., Brookmeyer, R., Kawas, C., 2005. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol. Aging 26, 157-163. (Pubitemid 39600576)